These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 12048959)

  • 1. Can J & J keep the magic going?
    Taylor A
    Fortune; 2002 May; 145(11):117-20, 122. PubMed ID: 12048959
    [No Abstract]   [Full Text] [Related]  

  • 2. The genetics of a pharma merger.
    Sanseau P; Chabot-Fletcher M; Browne MJ
    Drug Discov Today; 2009 Apr; 14(7-8):334-6. PubMed ID: 19121408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deal watch: M&A activity in 2009.
    Walker J
    Nat Rev Drug Discov; 2010 Feb; 9(2):95. PubMed ID: 20118956
    [No Abstract]   [Full Text] [Related]  

  • 4. Is it too late to save Schering?
    Simons J
    Fortune; 2003 Sep; 148(5):145-6, 148, 150. PubMed ID: 14509911
    [No Abstract]   [Full Text] [Related]  

  • 5. Hidden in plain view.
    Jacobs T
    Nat Biotechnol; 2003 Jun; 21(6):603. PubMed ID: 12776141
    [No Abstract]   [Full Text] [Related]  

  • 6. Ichan the spoiler.
    Creswell J
    Fortune; 2005 Mar; 151(6):195-6, 198. PubMed ID: 15782883
    [No Abstract]   [Full Text] [Related]  

  • 7. European pharma consolidation generates quality spinoffs.
    Sheridan C
    Nat Biotechnol; 2006 Dec; 24(12):1458-9. PubMed ID: 17160029
    [No Abstract]   [Full Text] [Related]  

  • 8. "Temptation is all around us".
    Vasella D
    Fortune; 2002 Nov; 146(10):109-10, 112, 114 passim. PubMed ID: 12455262
    [No Abstract]   [Full Text] [Related]  

  • 9. The closure of Sugen.
    Levitzki A
    Nat Biotechnol; 2003 Sep; 21(9):969. PubMed ID: 12949548
    [No Abstract]   [Full Text] [Related]  

  • 10. Merck's man in the hot seat.
    Simons J
    Fortune; 2004 Feb; 149(4):111-2, 114. PubMed ID: 14983668
    [No Abstract]   [Full Text] [Related]  

  • 11. Supply chain relationships and satisfaction in the agribusiness sector.
    Molnár A; Gellynck X
    Commun Agric Appl Biol Sci; 2006; 71(1):301-5. PubMed ID: 17191526
    [No Abstract]   [Full Text] [Related]  

  • 12. Baxter's healthy return. Morgan Stanley's Glenn Reicin says the medical products company's prognosis is finally positive.
    Stires D
    Fortune; 2004 Aug; 150(3):166. PubMed ID: 15357278
    [No Abstract]   [Full Text] [Related]  

  • 13. Executive pay trends and golden parachute tax: a collision on the horizon.
    Johnson DG
    Benefits Q; 2004; 20(1):30-6. PubMed ID: 15015423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A smarter way to buy.
    Degraeve Z; Roodhooft F
    Harv Bus Rev; 2001 Jun; 79(6):22-3, 145. PubMed ID: 11408975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategy: the key to financial payback from reengineering.
    Stickler MJ
    Hosp Mater Manage Q; 1996 Aug; 18(1):10-6. PubMed ID: 10159795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IT solutions for big Pharma's big headache.
    Krohn R
    J Healthc Inf Manag; 2005; 19(1):13-5. PubMed ID: 15682670
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmaceutical companies: safe stock market investments.
    Prescrire Int; 2012 Oct; 21(131):251. PubMed ID: 23185855
    [No Abstract]   [Full Text] [Related]  

  • 18. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 19. [The United States-European Union Transatlantic Trade and Investment Partnership and its possible effects on the Spanish health system].
    Navarro V
    Gac Sanit; 2015; 29(5):326-7. PubMed ID: 26068812
    [No Abstract]   [Full Text] [Related]  

  • 20. Roche vows to keep Genentech culture.
    Hayden EC
    Nature; 2009 Mar; 458(7236):270. PubMed ID: 19295574
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.